Video

Dr. Siegel on Drugs Discussed at the 2010 ASH Meeting

Author(s):

David S. Siegel, MD, PhD

David S. Siegel, MD, PhD, Chief, Multiple Myeloma at John Theurer Cancer Center, on new drugs discussed at the 2010 American Society of Hematology Conference.

David S. Siegel, MD, PhD, Chief, Multiple Myeloma at John Theurer Cancer Center, on new drugs discussed at the 2010 American Society of Hematology (ASH) Conference.

Related Videos
Fred Saad, CQ, MD, FRCS, FCAHS
Lillian L. Siu, MD, FRCPC
Marc Machaalani, MD
Mark Awad, MD, PhD, chief, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center
Rasha Cosman, BSc, MBBS, FRACP
Saad Z. Usmani, MD, MBA, FACP, FASCO
Nicholas P. McAndrew, MD, MSCE
Xichun Hu, MD, PhD
Nicolas Girard, MD
Binod Dhakal, MD
Related Content
Steven A. Shallcross
October 3rd 2024

Ribaxamase Shows Safety in the Prevention of aGVHD Following Allo-HSCT

OncLive On Air
March 18th 2024

Revisit the OncLive On Air Episodes From February 2024

Stephan Braun, MD, PhD
September 18th 2024

FDA Grants Fast Track Designation to ICT01 Plus Azacitidine/Venetoclax in Treatment-Naive AML

Matthew Lunning, DO, FACP
November 30th 2023

Lunning and Jacobson Dissect the Role of CAR T-Cell Therapy in Follicular Lymphoma

Christopher A. Yasenchak, MD, of of Willamette Valley Cancer Institute and Research Center/US Oncology Research
September 7th 2024

Brentuximab Vedotin Triplet Continues to Improve R/R Diffuse Large B-Cell Lymphoma Outcomes

Jason R. Westin, MD, of The University of Texas MD Anderson Cancer Center
September 7th 2024

Frontline Golcadomide/R-CHOP Combo Elicits Antitumor Activity in Aggressive B-Cell Lymphoma